Quest Diagnostics Incorporated Revenue in 2025

Quest Diagnostics Incorporated reported $11.0B in revenue for fiscal year 2025. This represents a growth of 11.8% compared to the 2024 figure of $9.9B.

Quest Diagnostics Incorporated, the Secaucus, New Jersey-based diagnostic information services giant, has transformed from a small pathology laboratory founded by a single physician in 1967 into a $11.04 billion enterprise that influences 70-80% of physician treatment decisions through its laboratory testing results. For fiscal year 2025, Quest Diagnostics reported net revenues of $11.035 billion, an 11.8% increase from $9.872 billion in 2024. Operating income surged 15.6% to $1.556 billion, with operating margin improving to 14.1% from 13.6%. Net income attributable to the company rose 13.9% to $992 million, and diluted earnings per share increased 13.8% to $8.75. On an adjusted basis, operating income grew 14.1% to $1.759 billion (15.9% margin), and adjusted diluted EPS rose 10.3% to $9.85. Cash provided by operations exploded 41.4% to $1.886 billion, reflecting strong earnings growth and working capital improvements. The company's fiscal 2026 guidance, raised in April 2026 after a strong first quarter, now calls for net revenues of $11.70-$11.82 billion (6.0-7.1% growth), reported diluted EPS of $9.45-$9.65, and adjusted diluted EPS of $10.50-$10.70. Cost of services was $7.370 billion in 2025 (66.8% of revenue), yielding a gross service margin of approximately 33.2%. Selling, general, and administrative expenses were $1.967 billion (17.8% of revenue). Amortization of intangible assets was $154 million. The company generated $1.886 billion in cash from operations and spent $527 million on capital expenditures, yielding substantial free cash flow of approximately $1.36 billion. Capital allocation priorities include dividends ($353 million paid in 2025), share repurchases ($450 million), acquisitions ($101 million in 2025, though the LifeLabs acquisition closed in August 2024), and debt management. The August 2024 acquisition of LifeLabs for approximately CAD $1.35 billion (USD ~$1 billion) added Canada's leading laboratory diagnostic provider with over 6,500 employees, more than 8 million online portal users, and approximately CAD $970 million in annual revenue. The company has grown through decades of acquisitions into an $11.04 billion revenue enterprise employing approximately 50,000 people. For fiscal year 2025 (ended December 31, 2025), Quest Diagnostics reported net revenues of $11.035 billion, operating income of $1.556 billion, and net income attributable to the company of $992 million. The Diagnostic Information Services segment generated $10.785 billion (97.7% of revenue). Key 2024-2025 developments include the CAD $1.35 billion acquisition of LifeLabs (Canada's leading lab provider), the acquisition of Fresenius Medical Care's Spectra Laboratories renal testing assets, and the launch of AD-Detect Alzheimer's blood tests. The company trades on the NYSE under ticker DGX with a market cap of approximately $19 billion. For fiscal year 2025, the Diagnostic Information Services segment generated $10.785 billion in revenue (97.7% of consolidated net revenues), with the remainder coming from corporate and other activities. Cost of services was $7.370 billion in 2025 (66.8% of revenue), comprising laboratory personnel, reagents and consumables, specimen collection and transportation, equipment depreciation, and facility costs. Selling, general, and administrative expenses were $1.967 billion (17.8% of revenue), covering sales forces, billing and collections, customer service, and corporate overhead. Amortization of intangible assets was $154 million, reflecting the substantial goodwill and intangible assets accumulated through decades of acquisitions. This model has been executed with NewYork-Presbyterian ($275 million), Memorial Hermann, Hackensack Meridian Health, Mercy, Steward Health Care System, and numerous others. Quest Diagnostics Incorporated is generating $11.04 billion in annual revenue with 15.9% adjusted operating margins while processing over 220 million diagnostic requisitions annually and maintaining clinical laboratory data on more than 65% of the U.S. Population — the most comprehensive health data repository outside government agencies. The company's fiscal 2025 results demonstrated strong execution: revenue grew 11.8%, operating income surged 15.6%, and cash from operations exploded 41.4% to $1.89 billion. The August 2024 acquisition of LifeLabs for CAD $1.35 billion established Quest as the dominant laboratory provider in Canada, while the 2025 Spectra Laboratories acquisition from Fresenius Medical Care expanded renal testing to 200,000+ dialysis patients. Relative to LabCorp, Quest is larger in absolute revenue ($11.04 billion vs. LabCorp's approximately $12-13 billion, though LabCorp includes drug development services through its Covance division). For fiscal year 2025 (ended December 31, 2025), Quest Diagnostics Incorporated reported net revenues of $11.035 billion, an 11.8% increase from $9.872 billion in 2024. The company reported operating income of $1.556 billion, a 15.6% increase from $1.346 billion in 2024. Net income attributable to Quest Diagnostics was $992 million, up 13.9% from $871 million in 2024. Diluted earnings per share were $8.75, up 13.8% from $7.69. On an adjusted basis, which excludes restructuring and integration charges, amortization, and other special items, operating income was $1.759 billion (15.9% margin), up 14.1% from $1.541 billion (15.6% margin) in 2024. Adjusted net income attributable to the company was $1.118 billion, up 10.5% from $1.011 billion. Adjusted diluted EPS was $9.85, up 10.3% from $8.93. Cost of services was $7.370 billion in 2025 (66.8% of revenue), up 11.2% from $6.628 billion in 2024. Selling, general, and administrative expenses were $1.967 billion (17.8% of revenue), up 11.1% from $1.770 billion. Amortization of intangible assets was $154 million, up from $127 million, reflecting the LifeLabs acquisition and other deals. Other operating income was $12 million in 2025 compared to $1 million in expense in 2024, driven by litigation recoveries and asset sales. Interest expense, net was $264 million, up from $201 million, reflecting higher debt levels from the LifeLabs acquisition. Other income, net was $26 million, down from $30 million. The effective tax rate on a GAAP basis was 23.8% ($314 million tax expense on $1.318 billion pre-tax income), compared to 23.2% in 2024. Equity in earnings of equity method investees, net of taxes, was $42 million, up from $19 million. Net income attributable to noncontrolling interests was $54 million, up from $50 million. Cash provided by operating activities was $1.886 billion, up 41.4% from $1.334 billion in 2024. Capital expenditures were $527 million, up 23.8% from $425 million, driven by laboratory equipment purchases, facility upgrades, and technology investments. Free cash flow (operating cash flow minus capital expenditures) was approximately $1.36 billion. Business acquisitions, net of cash acquired, were $101 million in 2025, down from $2.164 billion in 2024 (which primarily reflected the LifeLabs acquisition). Cash used in financing activities was $1.388 billion, reflecting debt repayments ($1.012 billion), treasury stock purchases ($450 million), dividend payments ($353 million), and other items offset by borrowings ($410 million). The balance sheet as of December 31, 2025, showed cash and cash equivalents of approximately $135 million (down from higher levels due to acquisition financing and capital deployment). The company has guided fiscal 2026 net revenues to $11.70-$11.82 billion (6.0-7.1% growth), reported diluted EPS to $9.45-$9.65, and adjusted diluted EPS to $10.50-$10.70. Cash provided by operations is expected to be approximately $1.75 billion, with capital expenditures of approximately $550 million. With $11+ billion in annual revenue, $1.9 billion in operating cash flow, and an investment-grade balance sheet, Quest can fund technology investments, acquisition opportunities, and pricing strategies that smaller competitors cannot match. The company's ability to acquire LifeLabs for CAD $1.35 billion and Spectra Laboratories assets while maintaining dividend growth and share repurchases demonstrates financial flexibility. Quest has executed dozens of hospital outreach acquisitions, including recent deals with NewYork-Presbyterian ($275 million), Steward Health Care System, Allina Health, and numerous regional health systems. The company generates approximately $1.75 billion in annual operating cash flow and guides capital expenditures of approximately $550 million, leaving substantial free cash flow for dividends, share repurchases, and acquisitions. Share repurchases of $450 million in 2025 demonstrate commitment to returning capital. The fiscal 2026 guidance of $11.70-$11.82 billion in revenue and $10.50-$10.70 in adjusted diluted EPS, raised in April 2026 after strong first quarter results, signals management confidence in execution. LifeLabs generates approximately CAD $970 million in annual revenue and serves millions of Canadians through patient service centers and online portals. But the defining deal was the 1999 acquisition of SmithKline Beecham Clinical Laboratories (SBCL) for approximately $1.3 billion in cash and stock. SBCL had generated $1.6 billion in revenue in 1998 and added a national network of regional laboratories, specialty testing operations, STAT laboratories, patient service centers, and — uniquely — a medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) founded in 1988. SmithKline Beecham received approximately $1.0 billion in cash and 12.6 million newly issued shares, holding approximately 29% of Quest's outstanding stock post-transaction. In 2002, the company acquired American Medical Laboratories, Inc. (AML) and LabPortal, Inc. For $500 million. The Unilab acquisition required divestiture of certain Northern California assets to LabCorp for $4.5 million to satisfy antitrust concerns. In 2005, Quest acquired LabOne, Inc. For $934 million, adding employer drug testing and paramedical testing capabilities. In 2006, the company acquired Focus Diagnostics for $185 million, strengthening infectious and immunologic disease testing. In 2007, Quest made two significant acquisitions: Hemocue (point-of-care diagnostic testing, Sweden) and AmeriPath (cancer diagnostic testing) for approximately $1.23 billion. In 2020, Quest acquired Blueprint Genetics (Helsinki, Finland) for $108 million, adding genetic testing capabilities for rare diseases. In 2023, the company acquired Haystack Oncology, a minimal residual disease testing company, and the outreach operations of NewYork-Presbyterian Hospital for $275 million. In 2024, the company acquired select assets of Steward Health Care System's outreach lab business, Lenco Diagnostic Laboratories in Brooklyn, and — most significantly — LifeLabs from OMERS for CAD $1.35 billion.